Liquid biopsy is a promising tool for diagnosing diseases. However, there are some big challenges that make it hard to use widely:
Sensitivity and Specificity: Right now, the technology might miss tiny amounts of ctDNA (circulating tumor DNA). This can result in false negatives, meaning that it might say there’s no problem when there actually is one.
Standardization: Different ways of processing and testing samples can lead to mixed results. This makes it hard to trust the results.
Regulatory Hurdles: There aren’t enough strong rules and guidelines to help bring these tests into regular use. This slows things down.
By improving techniques and making stricter regulations, we can make liquid biopsy more reliable. This would help more doctors and patients benefit from these tests.
Liquid biopsy is a promising tool for diagnosing diseases. However, there are some big challenges that make it hard to use widely:
Sensitivity and Specificity: Right now, the technology might miss tiny amounts of ctDNA (circulating tumor DNA). This can result in false negatives, meaning that it might say there’s no problem when there actually is one.
Standardization: Different ways of processing and testing samples can lead to mixed results. This makes it hard to trust the results.
Regulatory Hurdles: There aren’t enough strong rules and guidelines to help bring these tests into regular use. This slows things down.
By improving techniques and making stricter regulations, we can make liquid biopsy more reliable. This would help more doctors and patients benefit from these tests.